2024
DOI: 10.1002/hem3.130
|View full text |Cite
|
Sign up to set email alerts
|

Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma

Inna Y. Gong,
Daisy Tran,
Samuel Saibil
et al.

Abstract: CD19‐directed autologous chimeric antigen receptor T cell (CAR‐T) therapy has transformed the management of relapsed/refractory (R/R) large B cell lymphoma (LBCL). Initially approved in the third line and beyond setting, CAR‐T is now standard of care (SOC) for second‐line treatment in patients with refractory disease or early relapse (progression within 12 months) following primary chemoimmunotherapy. Despite becoming SOC, most patients do not achieve complete response, and long‐term cure is only observed in a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 134 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?